AstraZeneca's Imfinzi Combo Approved In US For Muscle-Invasive Bladder Cancer Treatment
Neutral
0.0
(RTTNews) - British drug major AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in th
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
